Effect of Obestatin on Bone Turnover in Normal and Obese Male Albino Rats

SAMA S. KHALIL, M.D. and REHAM H. IBRAHIM, M.D.
The Department of Physiology, Faculty of Medicine, Zagazig University, Egypt

Abstract

Background: Obestatin is a peptide hormone derived from the posttranslational cleavage of the same peptide precursor as ghrelin, it has been shown to regulate food intake, pancreatic, adipocyte, cardiac function as well as cell proliferation, however, to date, no studies have shown the effect of obestatin on bone turnover.

Aim of Study: This work was designed to investigate the effects of obestatin on bone metabolism in normal and obese rats and to explain the possible underlying mechanisms.

Material and Methods: Experiments conducted on 32 healthy adult male albino rats, which were randomly and equally divided into 2 groups, group I (normal) and group II [high fat diet induced obese group (HFD)]. Each group further subdivided into equal 2 subgroups: Group a (received a single intraperitoneal (ip) injection of 100ml saline daily for 30 consecutive days) and group b (daily ip injected with obestatin “1nmol/100gm BW” for 30 consecutive days). In all groups, gene expression of osteocalcin (OC), osteoprotegerin (OPG) and Receptor activator nuclear factor κB ligand (RANKL) bone markers were measured by real time PCR (RT-PCR), serum calcitonin, interleukin-6 (IL-6), insulin, glucose, total cholesterol (TC), total triglycride (TG) were measured, HOMA-IR and BMI were calculated, bone histopathology was also done.

Results: In both normal and obese groups, obestatin caused significant decrease in RANKL, significant increase in osteoprotegerin, OPG/RANKL ratio, osteocalcin expression and serum calcitonin in comparison to their control, in subgroup Ib (obestatin treated normal group), there was significant decrease in BMI, however, there was non-significant change in serum glucose, insulin levels, HOMA-IR index, TC, TG, IL 6 levels in comparison to subgroup Ia. While, in subgroup IIb (obestatin treated obese group), there was a significant decrease in BMI, serum glucose, TG, TC, serum insulin levels, HOMA-IR index and IL 6 levels in comparison to subgroup IIa. In bone histopathology, subgroup Ib showing slight increase in bone trabeculae thickness in comparison to the control and subgroup IIa showed thin atrophic bone trabeculae with wide marrow spaces. While, subgroup IIb showed increased bone trabeculae thickness in comparison to the later.

Conclusion: Obestatin has anabolic effect on bone in normal and obese rats, which can it be used in regime diet induced weight loss, as it prevent the decrease of bone mass that accompany weight loss.

Key Words: Obestatin – Bone turnover – Osteocalcin – Osteoprotegerin – RANKL.

Introduction

It is interesting that adequate nutrient intake and normal gastrointestinal function are critical to bone health, which can be under constant repair and remodeling. Gut hormones may integrate a connection between food intake and bone turnover, this help in the management of the secondary causes of bone diseases associated with nutritional disturbance [1].

Obestatin (OBST) is a 23-amino-acid, peptide hormone that is mainly produced in the gastrointestinal tract and is derived from the posttranslational cleavage of the same peptide precursor of ghrelin [2]. OBST has been shown to regulate metabolic function at the central and the peripheral levels, which includes regulation of food intake and pancreatic, adipocyte, and cardiac function as well as cell proliferation [2-4]. It has been reported to bind to and activate the orphan G protein-coupled receptor-39 (GPR39), as well as the glucagon-like peptide-1 receptor (GLP1R) and growth hormone secretagogue receptor (GHSR) [2,6,7].

This protein and its receptors are expressed on osteoblastic cell lines in different stages of maturity [8]. Moreover, in osteoblastic cell culture, there was increase in bone turnover markers (BTMs) production on exposure to OBST, with increased cell viability [1,9], these data reinforce the hypothesis that bone function might be under the influence of OBST released in response to changes in dietary intake [1,9].

It is interesting that obesity have adverse effects on bone health, as there is a negative associations
between excess fat and bone mineral density (BMD), bone geometry and bone strength [10,11]. OBST appears to play an important role with clear potential relevance to obesity, as it prevent lipolysis and acts similarly to insulin, reduced insulin resistance and reduced inflammation in metabolic tissue [6].

The aim of this study is to determine the effect of OBST administration on bone metabolism in normal and high fat diet induced obese rats.

**Material and Methods**

In the period from 15th February to 13th July 2018, the study was performed in the animal house of Faculty of Medicine, Zagazig University and involved 32 healthy adult male albino rats of local strain weighting (193±9.14gm). All animals received care in compliance with the animal care guidelines and ethical regulations in accordance with the guide for the care and use of laboratory animals according to Institute of Laboratory Animal Resources, [12], the animals were housed in plastic cages under controlled hygienic conditions with an ambient temperature (22±2°C) and normal light/dark cycles with free access to food and water throughout the period of the study. After acclimation for one week, the rats were divided into 2 major equal groups:

**Group I:** Rats were fed on standard chow diet (5% of energy derived from fat, 18% from proteins, and 77% from carbohydrates; 3.3kcal/g), then it divided into two subgroups (n=8)/each. Subgroup (Ia) (the normal control group): Each rat received intraperotoneal (ip) injection of 100ml of saline "NaCl 0.9%" daily for 30 consecutive days. Subgroup (Ib) (OBST-treated normal group): Each rat received ip daily dose of obestatin (1nmol/100gm BW dissolved in 100ml saline) (Sigma Aldrich Co.-USA) for 30 consecutive days [13].

**Group II:** Rats were fed high fat diet (HFD) (Faculty of Agriculture, Zagazig University) (60% fat, 21% carbohydrate, 18% protein and 5.1 calories/g) for 10 weeks to induce obesity [14], then it divided into two subgroups (n=8)/each.

**Subgroup (IIa) (the obese control group):** Each rat received ip injection of 100ml of saline "NaCl 0.9%" daily for 30 consecutive days. Subgroup (IIb) (OBST-treated obese group): Each rat received ip daily dose of obestatin (1nmol/100gm BW dissolved in 100ml saline) (Sigma Aldrich Co.-USA) for 30 consecutive days [13].

**Experimental design:** 24 hours after the last injection of OBST, blood samples were collected from retro-orbital venous plexus and serum was separated by centrifugation of clotted blood at 3000rpm for 20 minutes. The serum was kept deep frozen at (~80°C) until biochemical serum analysis. Afterward, the animals were stunned and killed by a sharp blow to the head; the tibiae were extracted and quick-frozen at (~70°C) until total RNA isolation.

Then the femur was removed from each rat, cleaned of adhering soft tissue, fixed and placed in 10% formalin solution for bone histopathology.

Quantitative analysis of gene expression of RANKL and Osteocalcin by real time PCR: According to krassmann et al., [15].

**Total RNA extraction**: Quick-frozen tibia were transported from ~70°C storage to liquid nitrogen until it was divided into two equal portions by diagonal pliers, one portion was individually powdered with a cold steel mortar and pestle, total RNA was extracted from tissue homogenate using SV Total RNA Isolation System (Promega, Madison, WI, USA) according to manufacturer's instruction. The RNA concentrations and purity were measured with an ultraviolet spectrophotometer.

**Complementary DNA (cDNA) synthesis**:

The cDNA was synthesized from 1 µg total RNA using SuperScript III First-Strand Synthesis System as described in the manufacturer’s protocol (#K1621, Fermentas, Waltham, MA, USA). In brief, 1 µg total RNA was mixed with 50 µM oligo (dT) 20, 50ng/µl random primers, and 10 mM dNTP mix in a total volume of 10 µl. The mixture was incubated at 56°C for 5min, and then placed on ice for 3min. The reverse transcriptase master mix containing 2 µl of 10 x RT buffer, 4 µl of 25mM MgCl2, 2 µl of 0.1 M DTT, and 1 µl of SuperScript® III RT (200 U/ µl) was added to the mixture and was incubated at 25°C for 10min followed by 50min at 50°C.

**Real-time quantitative PCR**:

Real-time PCR amplification and analysis were performed using an Applied Biosystem with software version 3.1 (StepOneTM, USA). The reaction contained SYBR Green Master Mix (Applied Biosystems), gene-specific primer pairs which were shown in Table (1) and were designed with Gene Runner Software (Hasting Software, Inc., Hasting, NY) from RNA sequences from the gene bank. All primer sets had a calculated annealing temperature of 60°. Quantitative RT-PCR was performed in a 25-µl reaction volume consisting of 2X SYBR Green PCR Master Mix (Applied Biosystems),
900nM of each primer and 2 µl of cDNA. Amplification conditions were: 2 min at 50º, 10 min at 95º and 40 cycles of denaturation for 15 s and annealing/extension at 60º for 10 min. Data from real-time assays were calculated using the v1.7 sequence detection software from PE Biosystems (Foster City, CA). Relative expression of studied gene mRNA was calculated using the comparative Ct method. All values were normalized to beta actin which was used as the control housekeeping gene and reported as fold change over background levels detected in the examined groups.

- The primer sequence of the studied gene.

<table>
<thead>
<tr>
<th>Primer sequence</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANKL</td>
<td>Forward primer: 5'-GAGACTACGGCA AGTA-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5'-CCTCCAAGCTTATGG-3'</td>
</tr>
<tr>
<td>Osteoprotegerin (OPG)</td>
<td>Forward primer: 5'-TGGCACACACGTGA TGAATGG-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5'-GCTGGAAAGTTTGCTCT TGCG-3'</td>
</tr>
<tr>
<td>Osteocalcin</td>
<td>Forward: 5'-TGGAGCTCGAATTCTGC TTG-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5'-CATCAAGATGCGGAGTGCT-3'</td>
</tr>
<tr>
<td>Beta actin</td>
<td>Forward primer: 5'-GGTCGGTGTGAACGGATTTGG-3'</td>
</tr>
<tr>
<td></td>
<td>Reverse primer: 5'-ATGTAGGCCATGAGGTCCACC-3'</td>
</tr>
</tbody>
</table>

Anthropometric measures: Measuring body weight: The animal was put in closed plastic container and weighed one day before the experiment and at the last day. The results were recorded for each labeled rat. Measuring rat length: By metal ruler, nose to anus length was measured. Calculating BMI index: Body mass index (BMI) equals body weight (g)/length² (cm²), this index can be used as an indicator of obesity where the cut off value of obesity BMI is more than 0.68 g/cm² [16].

Serum analysis:

Serum calcitonin: By using rat calcitonin (CT) ELISA kits Cat. No. KT-8860 according to Zhou et al., [17].

Serum glucose level: According to Tietz et al., [18] using glucose enzymatic (GOD-PAP) liqzyme Kits (Biotecnology, Egypt).

Serum insulin level: By a solid phase enzyme amplified sensitivity immunoassay according to Temple et al., [19] using KAP1251-INS-EASIA (Enzyme Amplfied Saoitivity Immunoassay) Kits (BioSource Europe S.A., Belgium). HOMA-IR: Was assessed by homeostasis model assessment equation where [HOMA-IR=insulin (µU/mL) x glucose (mg/dL)/405] [20, 21]. Serum total cholesterol (TC) level: According to Tietz et al., [18] using rat cholesterol enzyme-linked immunosorbent assay kit, (BioSource Europe S.A.-Rue de l'Industrie, 8-B- 1400 Nivelles-Belgium). Serum triglycerides (TG) level: Using rat triglycerides enzyme-linked immunosorbent assay kit, (BioSource Europe S.A.-Rue de l'Industrie, 8-C- 1150 Nivelles-Belgium) according to Fossati and Prencipe [22]. Serum IL6: By using a double-antibody sandwich ELISA rat IL-6 kits according to Song et al., [23].

Bone histopathological sections:

The femur was removed from each rat, cleaned of adhering soft tissue, fixed and placed in 10% formalin solution for one day [24]. After proper fixation of the specimens, tissues were processed in ascending grades of alcohol, cleaned in paraffin blocks. 4 microns sections were cut on a standard rotatory microtome. Serial sections were stained by hematoxylin and eosin stain (H&E) and observed for histopathological changes as described by [25].

Statistical analysis: The data obtained in the present study were expressed as mean ± SD for quantitative variables and statistically analyzed by using SPSS program (version 18 for windows) (SPSS Inc. Chicago, IL, USA). One way analysis of variance (ANOVA) was done followed by LSD test to compare means of the different groups. p-value <0.05 was considered statistically significant.

Results

Effect of OBST on anthropometric and serum metabolic parameters: As shown in Table (1), subgroup Ib (OBST treated normal group): There was significant decrease in BMI (p<0.05), however, there was non-significant change in serum glucose, insulin levels, HOMA-IR, TC, TG, IL6 levels in comparison to subgroup Ia (normal control group).

In subgroup IIa: (Obese control group), there was a significant increase in BMI, serum glucose, insulin levels, HOMA-IR, TC, TG, IL6 levels (p<0.001) in comparison to both subgroup Ia and subgroup Ib.

In subgroup IIb: (OBST treated obese group), there was a significant decrease in BMI, serum glucose, insulin levels, HOMA-IR index, TC, TG, IL6 levels in comparison to subgroup Ia (normal control group).

In subgroup IIa: (Obese control group), there was a significant increase in BMI, serum glucose, insulin levels, HOMA-IR index and IL6 levels (p<0.001) in comparison to both subgroup Ia and subgroup Ib.

In subgroup IIb: (OBST treated obese group), there was a significant increase in BMI (p<0.01) in comparison to subgroup Ia, in addition, there was...
significant increase in serum glucose, TG (p<0.001), TC and HOMA-IR index (p<0.05) in comparison to subgroup Ia and Ib.

Effect of OBST administration on gene expression of RANKL, Osteopetrogenin and Osteocalcin by real time PC: As shown in Table (2), subgroup Ib, there was a significant decrease in RANKL (p<0.05), however, there was significant increase in both Osteopetrogenin, OPG/RANKL ratio and Osteocalcin (p<0.05) in comparison to subgroup Ia. In subgroup Ia, there was a significant increase in RANKL (p<0.05), however, there was significant decrease in Osteopetrogenin, OPG/RANKL ratio and Osteocalcin (p<0.05) in comparison to both subgroup Ia and subgroup Ib.

In subgroup IIa, there was a significant decrease in RANKL (p<0.05) in comparison to subgroup IIa, while significant increase in RANKL (p<0.05) in comparison to subgroup Ib. In addition, there was significant increase in Osteopetrogenin, OPG/RANKL ratio and Osteocalcin (p<0.05) in comparison to subgroup IIa, while significant decrease in the same parameters (p<0.05) in comparison to subgroup Ib.

Effect of OBST on serum level of Calcitonin:
As presented in Table (3), subgroup Ib, there was a significant increase in serum calcitonin (p<0.05) in comparison to subgroup Ia. In subgroup IIa, there was significant decrease in calcitonin (p<0.05) in comparison to subgroup Ib. In subgroup IIb, there was significant increase in calcitonin (p<0.05) in comparison to subgroup IIa.

Histopathological examination:
The photomicrographs of normal control rats showing normal thick bone trabeculae with bone marrow spaces in between (Fig. 1), obestatin treated normal rats showing slight increase in bone trabeculae thickness in comparison to normal control rats (Fig. 2). Obese control rats showed thin atrophic bone trabeculae with wide marrow spaces (Fig. 3). OBST treated obese rats showed increased bone trabeculae thickness in comparison to obese control rats (Fig. 4).

Table (1): Effect of OBST on anthropometric and serum metabolic parameters in all groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Groups</th>
<th>Subgroup Ia (normal control)</th>
<th>Subgroup Ib (OBST treated)</th>
<th>Subgroup Ia (OBST treated)</th>
<th>Subgroup Ib (OBST treated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (g/cm²)</td>
<td></td>
<td>0.58±0.06</td>
<td>0.49±0.07±ab</td>
<td>0.81±0.04±ab</td>
<td>0.61±0.07±bc***</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td></td>
<td>93±6.6</td>
<td>91±3.1</td>
<td>188±2.5±ab***</td>
<td>130±4.2±abc***</td>
</tr>
<tr>
<td>Insulin (µU/ml)</td>
<td></td>
<td>11.93±1.77</td>
<td>11.33±6.4</td>
<td>21.33±0.91±ab***</td>
<td>13.6±0.2±c**</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td>2.7±0.07</td>
<td>2.54±1.03</td>
<td>9.9±0.25±ab***</td>
<td>4.36±0.7±abc***</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td></td>
<td>89.27±10.6</td>
<td>84±8.2</td>
<td>152±13.23±ab***</td>
<td>102.5±11.08±ab***</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td></td>
<td>65.50±15.3</td>
<td>67±11.6</td>
<td>140.83±1.15±ab***</td>
<td>95.01±8.91±abc***</td>
</tr>
<tr>
<td>IL6 (pg/ml)</td>
<td></td>
<td>46.9±13.3</td>
<td>43.2±10</td>
<td>69±12±ab***</td>
<td>51±9±**</td>
</tr>
</tbody>
</table>

(a)=Significant vs. group Ia. (b)=Significant vs. group Ib. (c)=Significant vs. group IIa.

Table (2): Effect of OBST on gene expression of RANKL, Osteopetrogenin and Osteocalcin by real time PCR in all groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Groups</th>
<th>Subgroup Ia (normal control)</th>
<th>Subgroup Ib (OBST treated)</th>
<th>Subgroup Ia (OBST treated)</th>
<th>Subgroup Ib (OBST treated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANKL</td>
<td></td>
<td>0.95±0.18</td>
<td>0.88±0.22±a</td>
<td>1.7±0.46±ab</td>
<td>0.97±0.33±bc*</td>
</tr>
<tr>
<td>Osteopetrogenin</td>
<td></td>
<td>0.9±0.16</td>
<td>1.4±0.52±a</td>
<td>0.65±0.17±ab*</td>
<td>0.95±0.22±bc*</td>
</tr>
<tr>
<td>OPG/RANKL Ratio</td>
<td></td>
<td>0.94±0.08</td>
<td>1.5±0.12±a</td>
<td>0.38±0.26±ab*</td>
<td>0.97±0.1±bc*</td>
</tr>
<tr>
<td>Osteocalcin</td>
<td></td>
<td>1.1±0.56</td>
<td>1.6±0.43±a</td>
<td>0.45±0.18±ab*</td>
<td>1.2±0.25±bc*</td>
</tr>
</tbody>
</table>

(a)=Significant vs. group Ia. (b)=Significant vs. group Ib. (c)=Significant vs. group IIa.

Table (3): Effect of OBST on serum level of Calcitonin (ng/dl) in all groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Groups</th>
<th>Subgroup Ia (normal control)</th>
<th>Subgroup Ib (OBST treated)</th>
<th>Subgroup Ia (OBST treated)</th>
<th>Subgroup Ib (OBST treated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcitonin (ng/dl)</td>
<td></td>
<td>42±3.5</td>
<td>49±2.8±a</td>
<td>36±2.2±b*</td>
<td>45±3.1±c*</td>
</tr>
</tbody>
</table>

(a)=Significant vs. group Ia. (b)=Significant vs. group Ib. (c)=Significant vs. group IIa.
Discussion

The present study demonstrated bone anabolic effect of OBST in both normal and HFD induced obese rats, OBST modulated bone metabolism by changes in bone turnover markers (BTMs), which are either by-products of collagen formation or breakdown, or cell proteins that reflect osteoclastic or osteoblastic activity, changes in BTMs reflect alterations in bone metabolism [26].

It is worth saying that, chronic OBST administration for 1 month in normal rats, increased bone trabecular thickness indicated in bone histopathology, in addition, it increased bone osteocalcin gene expression, which is the most abundant non-collagenous protein in bone [27]. Osteocalcin is produced by osteoblasts and is widely accepted as a marker of bone osteoblastic activity, it play an important role in bone formation, importantly, in the differentiation of osteoblast progenitor cells and in bone matrix synthesis and mineralization process [27,28].

One of the key regulators of bone resorption is the RANK/RANK ligand system [2]. Receptor activator nuclear factor κB (RANK) is a receptor expressed on the cell membrane of osteoclast precursors and mature osteoclasts, and its activation stimulates osteoclast differentiation and activity [3]. RANK ligand (RANKL) is secreted by stromal cells or osteoblasts and is the major paracrine factor in activating the RANK system in the osteoclast bone remodelling unit that increase bone resorption [31]. Many of the important regulators of bone resorption may act through the alteration of the relative amounts of RANKL secreted by osteoblasts [32-34].

Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor [35], it functions as a trap receptor by binding RANKL on osteoblast/stromal cells, it blocks the RANKL-RANK interaction between osteoblast/stromal cells and osteoclast precursors, so OPG prevents RANK- activa-
tion [36]. As a result, OPG can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors into osteoclasts and also regulates the resorption of osteoclasts [37]. In the current study, the chronic OBST administration decreased RANKL and increased Osteoprotegerin gene expression accompanied by increased OPG/ RANKL ratio.

Moreover, our results showed that OBST increased serum calcitonin, this may be through its action on GLP-1R [6], since GLP-1R is expressed in thyroid C cells [38]. One study documents that GLP-1R agonists cause calcitonin release in mice via a GLP-1R-dependent mechanism [39]. Calcitonin inhibits osteoclastogenesis [40], it is a known inhibitor of bone resorption, it can act directly on osteoblasts by increasing proliferation, and inhibiting RANKL mRNA expression [41].

The current study indicates that HFD induced obesity in subgroup IIa since the rise in TC and TG was associated with significant increase in BMI. Moreover, our results revealed significant increase in serum glucose, insulin, level of HOMA-IR in the same group. These results are in line with those of Sjoholm and Nystrom [42] and Eisinger, et al., [43] who noticed that HFD can cause development of many features of metabolic syndrome as disturbance in lipid metabolism and IR.

In addition, the results of this study indicate that obesity cause bone resorption as proved histopathological in obese group, showed thin atrophic bone trabeculae with wide marrow spaces, furthermore, real time PCR showed increased femur bone RANKL, decreased OPG and osteocalcin gene expression, with decreased OPG/RANKL ratio, these results were supported by Halade et al., [44] who reported that OPG secretion decreased and RANKL expression increased in osteoblasts stimulated with adipocyte-secreted factors.

Moreover, the current study reported increased IL6 level in the obese group, as obesity is considered a low grade pro-inflammatory state, associated with greater concentrations of pro-inflammatory cytokines [45]. The secretion of RANKL was regulated by cytokines as interleukin-1 (IL-1) [46], tumor necrosis factor [47] and IL-6 [48], inflammatory cytokines are positively associated with osteoclastogenesis as they upregulated RANKL mRNA expression in osteoblasts, consistent with osteoclast differentiation [49], enhance osteoclast activity and bone resorption [50,51]. As a result, inflammatory cytokines are negatively associated with bone strength [5] and positively associated with fracture risk [53].

Furthermore, obesity may decrease bone formation (osteoblastogenesis) while increasing adipogenesis because adipocyte and osteoblasts are derived from a common multi-potential mesenchymal stem cell [54]. Activation of peroxisome proliferator-activated receptor gamma (PPAR γ) decreased osteoblast differentiation, bone mineral density and trabecular bone mass while increasing adipocytes differentiation and bone marrow adipose tissue volume [55,56].

In addition, the increased IR reported in obese group may contribute to increased bone resorption, as insulin is a potential regulator of bone growth, it may act as an anabolic agent in bone and preserve bone mass in humans [57], insulin stimulates bone formation and osteocalcin secretion upon activation of insulin receptor signaling [58]. In addition, it decrease markers of bone resorption, this suggests that insulin may act as an anabolic agent for bone metabolism, by shifting the balance in the favor of bone formation [59].

In OBST treated obese group, there was increased osteocalcin and OPG gene expression, decreased RANKL expression, increased serum level of calcitonin were reported, in addition, bone histopathology showed increased bone trabecular thickness in comparison to obese control group.

OBST appears to play an important role with clear potential relevance to obesity and diabetes. Indeed, it is interesting that, OBST levels are reduced in obesity suggesting that it may be a nutritional marker reflecting body adiposity and IR [60, 61].

In the current study, OBST decreased factors that help bone resorption in obesity, as it decreased serum IL6, this result was in line with those of Zhang et al., [62] and supported by what reported by Ozge et al., [63] that OBST suppressed PMNL infiltration, inhibiting reactive oxygen radical generation and proinflammatory cytokine production, and provoking the synthesis of anti-inflammatory cytokines during the progression of both acute and chronic colitis.

Furthermore, OBST reduced HOMA-IR, our result are in line with those of Granata et al., [6], in addition, it inhibited the HFD-induced reduction of pancreatic islet area possibly because of its antiapoptotic and survival effects in β-cells, and strongly stimulated glucose-induced insulin secretion in pancreatic islets. The results of the present study showed a significant reduction in BMI, serum TG and TC in OBST-treated obese rats. Granata et al., [6] support this result as they reported that
in OBST-treated HFD fed mice, epididymal fat showed increased glucose uptake, increased number of small and likely insulin-sensitive adipocytes, and reduced lipolysis, so this protein appear to decrease risk factors that predispose to obesity and impaired bone quality.

Another mechanisms that may contribute to anabolic effect of OBST in normal and obese rats, it was reported that OBST can induce testosterone secretion in normal [13] and obese rats [66]. Low testosterone levels in boys have been associated with lower bone density [65].

Moreover, anabolic role of OBST on bone may be due to its enhancing effect on the expression of vascular endothelial growth factor (VEGF) and its receptor isomorf VEGFR2 in muscle [66]. VEGF is able to stimulate various aspects of bone development, including chondrocyte differentiation, osteoblast differentiation [67], in addition, it promote ossification by inducing neovascularisation and maximum levels of VEGF expression precede the maximum level of new bone formation in the condyle. This indicates a close correlation between vascularisation and bone formation [68,69]. Moreover, gene therapy explored in the condylar area, has shown that recombinant adeno-associated virus-mediated VEGF is an efficient delivery system to induce mandibular condylar growth [70].

Furthermore, OBST stimulate leptin secretion [71], leptin is an adipocyte-derived hormone that acts on receptors in the hypothalamus, decreasing food intake and increasing energy expenditure [72]. Central infusions of leptin in leptin-deficient receptor mice actually increase cortical bone formation and total bone mass, [73] however, leptin also has important peripheral and direct effects on osteoblasts and bone-derived mesenchymal stem (stromal) cells (BMSCs), as leptin treatment of leptin-sensitive BMSCs increases the expression of bone morphogenetic protein 2 (BMP-2) [74,75]. It was confirmed that leptin can promote osteoblast mineralization and down-regulate the RANKL mRNA expression [76].

Conclusion: In the present study, an apparent stimulation of bone remodeling favoring bone formation by obestatin in both normal and obese rats, the present data support antiresorptive character of obestatin and suggest that obestatin might be useful as a beneficial agent for improving the deficient bone formation and bone structure associated with obesity.

Acknowledgment:
To Prof/Kamal El-Kashishy, Pathology Department, Faculty of Medicine, Zagazig University, for performing the histopathological studies and to prof/Somiaa Hassan, Biochemistry Department, Faculty of Medicine, Zagazig University, for perform the laboratory tests.

References


Effect of Obestatin on Bone Turnover in Normal & Obese Male Albino Rats

334 Effect of Obestatin on Bone Turnover in Normal & Obese Male Albino Rats


تأثیر الأوبستاتین على أيض العظام في الجرذان الطبيعي والتصابة بالسمنة في ذكور الجرذان البيضاء البالغة

خلفية البحث: الأوبستاتین هو هرمون مشتق من نفس عائلة هرمون الجرذان وقد ثبت أنه يلعب دوراً رئيسياً في تنظيم الشهية للطعام ووظائف القلب والبنكرياس والنسج الدهني ولكن حتى الآن لا يوجد أي دراسات تتعلق بتأثير الأوبستاتین على أيض العظام.

الهدف من البحث: تهدف هذه الدراسة إلى استكشاف التأثیر المحتمل للأوبستاتین على أيض العظام في الجرذان البيضاء البالغة والتصابة بالسمنة وشرح الآليات المتعلقة بهذا التأثیر.

مواد وطرق البحث: تم استخدام 32 من ذكور الجرذان البيضاء البالغة. تم تقسيمها عشوائياً وتشكيل مجموعتين: مجموعة الأولى (الجرذان الطبيعي) والمجموعة الثانية (الجرذان الذي خضعت لنظام غذائي على الدهون لمدة 10 أسابيع). تنقسم كل مجموعة إلى 2 مجموعتين من فئتين مشتتتين: المجموعة A: تم حقنها يومياً بمحلول ملحي 100 مل لمدة 30 يوماً متناوبة والمجموعة B: تم حقنها يومياً باليوم الأخرى. GROUP B: يتم قياس نمط الجينات والدماغية المفصلية للجرذان في المجموعة A وAB بعد الانتهاء من الدراسة.

نتائج الدراسة: أظهرت الدراسات المختلفة أن الأوبستاتين يزيد دلتة إحساسية في النسيج العضلي وبيولياكتيفين في النسيج العضلي ومستوي الكاسالتين في مصل الدم، بينما منح تخسيس نقص دلة إحساسية في كتلة النسيج العضلي وأظهرت النتائج في مجموعات الجرذان المصابي بالسمة المعدية بالأوبستاتين وجود RANKL الجسم والمستقبلات الجيني لـ TLR3 متزايدة في المجموعتين. بينما لم تلاحظ نقص دلة إحساسية في نسيج القياس في مجموعات الجرذان المصابي بالأوبستاتين بالمقاومة مع المجموعة الأولى (A) وكمثل الأوبستاتين العضلي في المجموعة المعدية إلى الجرذان والجرذان المصابي بالسمة بالمقاومة مع المجموعة الأولى (A) خفضت الأوبستاتین التأثیر في نمط الجينات والدماغية المفصلية للجرذان الطبيعي التي تم تحضير الجرذان المصابي بالسمة المعدية بالمقاومة مع الجرذان الطبيعي لا يمتلك الأوبستاتين على الرغم من أن الأوبستاتين يمتلك أحدود الإحساسية في النسيج العضلي وبيولياكتيفين في المجموعة المعدية بالمقاومة مع الجرذان الطبيعي التي تم تحضيرها بالأوبستاتين زيادة في سكو لخلايا العظمية مقارنة بالجرذان الطبيعي والسمة.

الاستنتاج: نستخلص من هذه الدراسة أن الأوبستاتين يمكن أن يمتلك أخفض كتلة العظام في الجرذان الطبيعي والتصابة بالسمة، ويمكن استخدام الأوبستاتين في النظام الغذائي لأنه يمنع أخفض كتلة العظام التي تصبح بعد انسداد الوزن. 